Initial Treatment for Suspected ITP
For adults with newly diagnosed ITP requiring treatment, initiate corticosteroids as the cornerstone of first-line therapy, with consideration for adding rituximab or a thrombopoietin receptor agonist (TPO-RA) to the corticosteroid regimen based on the 2026 ASH guidelines. 1
Treatment Decision Framework
Step 1: Determine if Treatment is Necessary
Not all patients with suspected ITP require immediate treatment. Treatment should be initiated only for:
- Active bleeding
- Severe thrombocytopenia (typically platelet count <20-30 × 10⁹/L with bleeding risk)
- Need for invasive procedures
- Significantly diminished quality of life 2
Patients without bleeding and adequate platelet counts may be observed without treatment.
Step 2: First-Line Treatment Options for Adults
Standard Approach: Corticosteroids
The traditional backbone remains corticosteroids, but use short courses rather than prolonged treatment 3, 4:
Prednisone options:
- 0.5-2 mg/kg/day for a short course (typically ≤7 days)
OR Dexamethasone:
- 40 mg/day for 4 days
Enhanced Initial Therapy (2026 Update)
The most recent ASH 2026 guidelines now recommend combination therapy over corticosteroids alone 1:
Preferred combinations (conditional recommendation):
- Rituximab + corticosteroids, OR
- TPO-RA + corticosteroids
This represents a significant shift from the 2019 guidelines, which recommended corticosteroids alone as initial therapy 3. The newer evidence suggests combination therapy may improve long-term outcomes, though this is a conditional rather than strong recommendation, indicating moderate certainty in the evidence.
Alternative First-Line Agent: IVIG
- Intravenous immunoglobulin (IVIG) can be used as initial therapy, particularly when rapid platelet increase is needed or corticosteroids are contraindicated 2, 5
Step 3: Second-Line Treatment (After Corticosteroid Failure)
For patients who fail first-line corticosteroids (corticosteroid-dependent or non-responsive after ≥3 months):
Strong recommendation:
- TPO-RA (eltrombopag or romiplostim) - This is a strong recommendation from the 2026 guidelines 1
Conditional recommendation:
- Rituximab - Also supported but with conditional strength 1
The 2026 guidelines prioritize TPO-RAs over rituximab for second-line therapy, representing a change from earlier approaches where these were considered more equivalent options.
Critical Pitfalls to Avoid
Prolonged corticosteroid courses: The evidence strongly supports short courses (≤7 days) rather than extended tapers. Prolonged use increases toxicity without improving long-term outcomes 4
Delaying treatment in true emergencies: While observation is appropriate for stable patients, life-threatening bleeding requires immediate intervention with IVIG and/or corticosteroids
Rushing to splenectomy: Current guidelines favor TPO-RAs and rituximab over splenectomy for second-line therapy 1, 6. Splenectomy should be reserved for later lines given its irreversibility and surgical risks
Treating the platelet count instead of the patient: The goal is maintaining a safe platelet count to prevent bleeding, not normalizing counts. This minimizes treatment toxicity 4
Evidence Strength Considerations
The 2026 ASH guidelines 1 represent the most current evidence and should guide practice, though the combination therapy recommendations are conditional rather than strong, reflecting evolving evidence. The recommendation for TPO-RAs as second-line therapy is notably a strong recommendation, indicating high confidence in this approach for corticosteroid-refractory patients.
The shift toward combination initial therapy and prioritization of TPO-RAs reflects accumulating evidence that these approaches may improve sustained responses while avoiding the risks of splenectomy and prolonged immunosuppression.